NRAS
Biocartis, Merck KGaA Extend RAS Testing Partnership to Middle East, North Africa
The companies hope to improve access to biomarker testing to direct more personalized treatment for cancer patients in the region.
Researchers hope their study will show that tests for gene variants and DNA methylation can predict which lower-risk patients may be cured without a stem cell transplant.
Colon Cancer Biomarker Undertesting Rates in Real-World Data Points to Precision Oncology Barriers
Premium
The findings should spur cancer centers to review testing rates and address barriers, said experts from Hackensack University, Cota Healthcare, and Guardant Health.
Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.
Lung Cancer Panel From PlexBio Receives CE Mark
The assay can identify KRAS, NRAS, PIK3CA, BRAF, and EGFR gene mutations, as well as 19 gene rearrangements of the ALK, ROS1, RET, NTRK1, and MET genes from FFPE.